FDMT vs HD: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. FDMT and HD share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined FDMT and HD exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

4D Molecular Therapeutics, Inc. (Nasdaq: FDMT, and known as 4DMT) is an Emeryville, California biotech founded in 2013 that engineers adeno-associated virus (AAV) vectors through a directed-evolution platform the company calls Therapeutic Vector Evolution. Its lead candidate, 4D-150, pairs the proprietary R100 vector with a transgene encoding aflibercept plus an RNA interference approach against VEGF-C, delivered by a single in-office intravitreal injection. The goal is to replace repeated monthly or bimonthly anti-VEGF eye injections with one durable treatment. Two Phase 3 wet AMD trials are fully enrolled: 4FRONT-1 randomized 523 patients with topline data guided to Q2 2027, and 4FRONT-2 finished enrollment in June 2026 with more than 500 patients and topline guided to H2 2027. A Phase 3 in diabetic macular edema was slated to start in Q3 2026. Behind the retina franchise sit 4D-175 for geographic atrophy, 4D-710 for cystic fibrosis lung disease, and 4D-725 for alpha-1-antitrypsin deficiency, all of which the company says it is advancing mainly through outside funding rather than its own balance sheet.

Full FDMT guide

The Home Depot, Inc. is the world's largest home improvement retailer, operating approximately 2,300 stores across the United States, Canada, and other locations in North America. The company sells building materials, home improvement products, lawn and garden supplies, and provides installation and tool-rental services to two main customer groups: do-it-yourself homeowners (DIY) and professional contractors (Pros). Revenue is generated almost entirely through retail store sales and, increasingly, through digital channels (online sales reached 15.9% of total revenue in fiscal 2025) and through its specialty trade distribution arm, SRS Distribution, which serves Pros directly with roofing, landscaping, pool supplies, and now drywall and steel framing products following the September 2025 acquisition of GMS Inc. The company earns a gross margin of roughly 33% and an operating margin in the low-to-mid teens, with strong free cash flow that funds a steadily growing dividend (156 consecutive quarterly payments as of early 2026) and periodic share repurchases.

Full HD guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• FDMT drivers: Two fully enrolled Phase 3 wet AMD trials; Durability data that defines the commercial pitch.
• HD drivers: Pro contractor ecosystem buildout; Pent-up housing demand and a potential mortgage rate cycle turn.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Everything concentrates in one molecule and two readouts, so a miss or an ambiguous result in 4FRONT-1 or 4FRONT-2 would remove most of the reason to own the shares. For HD, the most direct risk is a prolonged freeze in the US housing market: low inventory, elevated mortgage rates, and high home prices have kept transaction volumes near multi-decade lows, directly suppressing demand for the large remodeling projects that drive Home Depot's highest-ticket sales.

Pick FDMT if you believe its drivers more; HD if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the FDMT and HD guides.

FDMT. Conventional multiples do not apply, because the revenue line is a licensing payment rather than a business. Stripping out roughly $431 million of cash and adding back $20 million of drawn Hercules debt leaves an enterprise value near $390 million on the common-share count, so the market was assigning a few hundred million dollars to a Phase 3 asset in a multi-billion-dollar indication plus four earlier programs. Book value is the only anchor with real content here, at roughly $408 million of stockholders' equity against an accumulated deficit of about $858 million, and the shares traded between roughly $5.97 and $15 over the trailing year.

HD. Home Depot grew total revenue 3.2% in fiscal 2025, but most of that growth came from the SRS and GMS acquisitions rather than organic comparable-store performance, which was essentially flat at +0.3%. Profitability softened modestly as acquisition-related costs, higher debt service, and integration expenses weighed on margins and pushed ROIC down from 31.3% to approximately 25.7%. The stock's trailing P/E of roughly 23x sits near its 10-year historical average and above the peer group, reflecting investor confidence in the long-term Pro strategy but leaving limited cushion if the housing market remains depressed longer than expected.

Headline figures (approximate, August 2026): FDMT shows revenue (ttm) ~$92M, of which ~$85M was a one-time Otsuka upfront, product revenue $0, no approved products since inception, net loss (q2 2026) ~$72.9M, ~$141.7M in H1 2026, r&d expense (q2 2026) ~$68.3M, versus ~$12.5M G&A; HD shows revenue (fiscal 2025, ended feb 1, 2026) ~$164.7 billion, net earnings (fiscal 2025) ~$14.2 billion, diluted eps (fiscal 2025) $14.23 (adjusted: $14.69), gross margin (fiscal 2026 guidance) ~33.1%.

FDMT and HD are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined FDMT and HD exposure against your real portfolio. It is not an investment adviser.